1stOncology™: Cancer Intelligence Service – Page 5961 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Synaffix Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards

On November 16, 2022 Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, reported the Company has been awarded ‘Biotech Company of the Year 2022’ at the annual LSX, European Lifestars Awards Ceremony, held on the 14th of November at the Old Billingsgate in London, UK (Press release, Synaffix, NOV 16, 2022, View Source [SID1234624142]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The European Lifestars Awards are instrumental in highlighting the incredible work being carried out across the life sciences industry. This award recognizes Synaffix’s pivotal year of growth and progress as it continues to develop and commercialize its proprietary ADC technology platforms.

Synaffix’ proprietary ADC technology platform consists of GlycoConnect, HydraSpace and toxSYN technologies. Both GlycoConnect and HydraSpace are clinical-stage technologies that enable best-in-class ADCs with significantly enhanced efficacy and tolerability. Together with the toxSYN linker-payloads, these three technologies provide developers with a "one stop" and easy-to-use ADC technology platform, allowing any antibody developer to develop its own proprietary, Best-in-Class ADC.

During the award qualification period (September 2021 to September 2022) Synaffix signed 5 ADC technology out-licensing deals with top tier biotech and pharma companies that come with a total combined potential value exceeding $2.5 Billion dollars, excluding the royalties payable on net sales of future products. These deals represent partnerships with companies including: Mersana Therapeutics, Genmab, Macrogenics, Kyowa Kirin and Emergence Therapeutics and comprise 5 of the 10 current partners developing ADC product candidates using Synaffix ADC technology. Synaffix continues to build its partnered pipeline as technology out-licensing is the primary focus of its corporate strategy to deliver best-in-class targeted cancer therapeutics from partner antibodies.

Scandion Oncology – Interim Report Q3 2022

On November 16, 2022 Scandion Oncology (Scandion) reported its interim report for Q3 2022 (Press release, Scandion Oncology, NOV 16, 2022, View Source;interim-report-q3-2022,c3667570 [SID1234624141]). The following is taken from the report.

Johnny Stilou, Acting CEO & CFO, comments

"In the third quarter of 2022 we managed to raise approximately 42 MDKK net in a very difficult stock market. The raised capital will take us well into 2024."

Shares outstanding, ending
Highlights during Q3 2022

On July 4, Scandion announced final outcome of its rights issue. Through the issue, Scandion raises approximately SEK 75 million before deduction of issue related costs.
On July 26, Scandion’s rights issue was registered with the Danish Business Authority.
On August 17, Scandion announced extension of the PANTAX trial due to better-than-expected tolerability of SCO-101.
On August 19, Scandion received approvals for next parts of the CORIST trial. The development of SCO-101 will continue as planned with expansion of the CORIST trial expected to commence during the third quarter of 2022.
On August 31, Scandion announced changes to Executive Management.
On September 31, Scandion announced topline results from part 2 of the CORIST phase II trial. Data from part 2 of the trial confirm the safety and tolerability of SCO-101. The trial will continue with part 3 exploring an optimized dosing schedule, aiming to utilize the full potential of SCO-101 in this indication and combination.
Highlights after the end of the period

On October 10, Scandion initiates recruitment in part 3 of the CORIST phase II trial.
On October 28, Scandion announce results of extraordinary general meeting.
The interim report Q3 2022 is available on the Company’s website: www.scandiononcology.com.

Audiocast today, November 16 at 10:00 am CET

Today at 10:00, Scandion Oncology’s executive management will host a webcast and conference call presenting the results and a company update.

At the end of the presentation there will be a Q&A session.

The information was provided by the contact person above for publication on November 16, 2022, at 08.30 CET.

Enterome announces presentation of data from ongoing Phase 1/2 trial of its peptide-based immunotherapy EO2401 in recurrent glioblastoma (ROSALIE study) at SNO 2022

On November 16, 2022 Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, reported that it will present updated efficacy, immunogenicity and safety data from its Phase 1/2 trial of EO2401 in combination with nivolumab +/- bevacizumab, in patients with first progression/recurrence of glioblastoma (ROSALIE trial) in an oral presentation at the 27th Society for Neuro-Oncology (SNO) Annual Meeting which will be held in Tampa Bay, Florida, US on November 16-20, 2022 (Press release, Enterome, NOV 16, 2022, View Source [SID1234624137]).

Oral Presentation Details – Abstract CTIM-17

Title: EO2401 therapeutic vaccine for patients with recurrent glioblastoma: phase 1/2 ROSALIE study (NCT04116658)
Authors: D. Reardon et al.
Date: November 18, 2022, 4:35 pm EST
Location: Tampa Convention Center, Ballroom B
Presenter: Prof. David Reardon, M.D., Professor of Medicine at Harvard Medical School, and Clinical Director for Dana Farber Cancer Institute
The abstract is published in a supplement to Neuro-Oncology, the Official Journal of the Society for Neuro-Oncology, and available via this link.

About EO2401

EO2401 is Enterome’s first-in-class off-the-shelf OncoMimics peptide-based immunotherapy. It combines three microbial-derived OncoMimics peptides that closely mimic specific cytotoxic T cell (CD8+ T cell) epitopes on the Tumor-Associated Antigens IL13Ra2, BIRC5 and FOXM1, combined with the helper peptide (CD4+ T cell epitope) Universal Cancer Peptide 2 (UCP2). EO2041 is designed to trigger the immune system into recognizing these epitopes on glioblastoma cells as foreign (non-self) and eliciting a targeted memory T-cell driven cell-killing response against the tumor cells.

Promising data presented during 2022 at ASCO (Free ASCO Whitepaper), ESMO (Free ESMO Whitepaper), EANO and SITC (Free SITC Whitepaper)

Data confirm that EO2401 in combination with nivolumab +/- bevacizumab is well tolerated with a safety profile consistent with the safety profiles of nivolumab and bevacizumab, with the addition of local administration site reactions.
EO2401 in combination with nivolumab generated strong systemic immune responses through activation of specific effector memory CD8+ T cells, correlating with efficacy.
Addition of bevacizumab, either as a low-dose symptom driven time-limited treatment, or as a continuous treatment at the labelled US dose, to EO2401 in combination with nivolumab supported longer treatment durations and an increase in efficacy.
CD8+ T cells against at least one of the EO2401 peptides was detected in 26 out of 28 patients with some patients exhibiting up to 5% of circulating specific CD8+ T cells. Memory specific CD8+ T cells response were found as early as two weeks after the first vaccination and maintenance of a strong and stable immune response could be detected for more than 10 months.
Additional patients are to be treated with triple combination of EO2401/nivolumab/bevacizumab to support final regimen selection for further studies.
About ROSALIE

ROSALIE (EOGBM1-18, NCT04116658) is a multicenter, open-label, Phase 1/2 trial investigating EO2401 in combination with nivolumab, and in combination with nivolumab/bevacizumab in patients with glioblastoma at first progression/recurrence after surgery and adjuvant radiotherapy/temozolomide. The trial is assessing safety, tolerability, immunogenicity and preliminary efficacy in approximately 80 patients at centers in the US and Europe.

Precision Biologics To Deliver Poster Presentations On Clinical And Scientific Programs At Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

On November 16, 2022 Precision Biologics, Inc. ("Precision"), a clinical-stage immunotherapy and targeted oncology company, reported that it will present at the SITC (Free SITC Whitepaper) 37th Annual Meeting (2022) in Boston, MA (Press release, Precigen, NOV 16, 2022, View Source [SID1234623581]).

The first poster presentation will discuss the novel target for its NEO-201 monoclonal antibody and mechanism of action for this drug including the specific O-glycan epitope recognized by NEO-201 and that NEO-201 kills target cells expressing core 1 and/or extended core 1 O-glycans through Antibody-Dependent Cellular Cytotoxicity (ADCC)

The second poster presentation will discuss the ongoing Phase 2 clinical trial being conducted at the National Cancer Institute that combines NEO-201 with Pembrolizumab in patients with treatment refractory solid tumors. The study is enrolling patients at the National Cancer Institute, Bethesda, MD, with metastatic Non-Small Cell Lung Cancer (NSCLC), Head and Neck Cancers, Endometrial Cancer and Cervical Cancer, who have already been treated with checkpoint inhibitor therapy (including prior Keytruda). (View Source)

Posters will be presented in person at the at the Boston Convention and Exhibition Center on Thursday November 10th, 2022.

NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates

On November 15, 2022 NextCure and LegoChem Biosciences reported a collaboration and co-development agreement focused on generating a B7-H4 antibody drug conjugate (ADC) and options for two additional targets (Press release, NextCure, NOV 15, 2022, View Source [SID1234638589]). The B7-H4 ADC will utilize NextCure’s B7-H4 antibody and LCB’s ConjuAllTM ADC technology.

Under the terms of the agreement, both parties will equally share the costs to develop the molecules and profits on commercialized products. The parties will utilize their respective product development capabilities to generate the B7-H4 ADC and advance it to the clinic. In addition, there are options for the parties to nominate two additional targets for ADC development beyond B7-H4.

"We are excited to work with LCB, and apply ConjuAllTM, a leading ADC technology, to add a new treatment modality to our B7-H4 program," said Timothy Mayer, NextCure’s Chief Operating Officer. "We remain committed to developing novel immunomedicines using multiple modalities to address the significant unmet needs of cancer patients not adequately addressed by available therapies."

"The initiation of this collaboration with NextCure represents another important milestone for LCB as we continue to build our ADC pipeline and seek to demonstrate the potential of our ADC platform in a wide range of different tumors," said Yong-Zu Kim, LCB’s Chief Executive Officer. "B7-H4 ADC would potentially offer a first-in-class opportunity for a target expressed on a broad range of tumor types, and I look forward to progress in early stage studies."